Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 4 | 2017 | 146 | 1.000 |
Why?
|
| Palliative Care | 5 | 2020 | 53 | 0.980 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 32 | 0.970 |
Why?
|
| Goals | 1 | 2020 | 27 | 0.650 |
Why?
|
| Estrogens | 4 | 2013 | 55 | 0.570 |
Why?
|
| Bone Density | 6 | 2014 | 93 | 0.560 |
Why?
|
| Body Composition | 12 | 2016 | 90 | 0.530 |
Why?
|
| Organizational Objectives | 1 | 2017 | 12 | 0.520 |
Why?
|
| Aged | 22 | 2020 | 5901 | 0.520 |
Why?
|
| Program Development | 1 | 2017 | 62 | 0.500 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 45 | 0.500 |
Why?
|
| Homosexuality | 1 | 2016 | 4 | 0.490 |
Why?
|
| Health Status Disparities | 1 | 2017 | 145 | 0.460 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 4 | 0.460 |
Why?
|
| Medication Therapy Management | 1 | 2015 | 5 | 0.450 |
Why?
|
| Obesity | 8 | 2016 | 811 | 0.420 |
Why?
|
| Homosexuality, Female | 1 | 2014 | 7 | 0.420 |
Why?
|
| Cultural Competency | 1 | 2014 | 12 | 0.420 |
Why?
|
| Bisexuality | 1 | 2014 | 11 | 0.420 |
Why?
|
| Social Work | 1 | 2014 | 15 | 0.410 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 38 | 0.410 |
Why?
|
| Humans | 38 | 2020 | 16832 | 0.410 |
Why?
|
| Transgender Persons | 1 | 2014 | 44 | 0.400 |
Why?
|
| Female | 33 | 2019 | 12193 | 0.400 |
Why?
|
| Weight Loss | 5 | 2016 | 302 | 0.380 |
Why?
|
| Exercise | 7 | 2014 | 513 | 0.360 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 393 | 0.350 |
Why?
|
| Middle Aged | 24 | 2017 | 7515 | 0.350 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 91 | 0.350 |
Why?
|
| Male | 20 | 2019 | 9556 | 0.330 |
Why?
|
| Postmenopause | 7 | 2014 | 243 | 0.330 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2013 | 11 | 0.320 |
Why?
|
| Saliva | 2 | 2005 | 11 | 0.280 |
Why?
|
| Social Workers | 2 | 2020 | 2 | 0.280 |
Why?
|
| Muscle, Skeletal | 4 | 2012 | 38 | 0.280 |
Why?
|
| Insulin | 7 | 2013 | 181 | 0.270 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 1887 | 0.250 |
Why?
|
| Adiposity | 3 | 2013 | 69 | 0.240 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 5 | 0.230 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 5 | 0.230 |
Why?
|
| Hydrocortisone | 1 | 2005 | 17 | 0.230 |
Why?
|
| Interviews as Topic | 2 | 2017 | 305 | 0.220 |
Why?
|
| Physical Endurance | 1 | 2003 | 4 | 0.200 |
Why?
|
| Hypogonadism | 1 | 2003 | 4 | 0.200 |
Why?
|
| Bone and Bones | 2 | 2014 | 10 | 0.200 |
Why?
|
| Colorado | 4 | 2019 | 171 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2013 | 6 | 0.180 |
Why?
|
| Blood Glucose | 5 | 2013 | 315 | 0.180 |
Why?
|
| Adult | 12 | 2016 | 7255 | 0.170 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 13 | 0.170 |
Why?
|
| Insulin Resistance | 2 | 2013 | 127 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 108 | 0.160 |
Why?
|
| Lipolysis | 2 | 2013 | 3 | 0.160 |
Why?
|
| Needs Assessment | 2 | 2014 | 64 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 48 | 0.150 |
Why?
|
| Dehydroepiandrosterone | 2 | 2011 | 7 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 60 | 0.150 |
Why?
|
| Caregivers | 1 | 2020 | 132 | 0.150 |
Why?
|
| Subcutaneous Fat | 2 | 2010 | 4 | 0.140 |
Why?
|
| Glycerol | 4 | 2013 | 5 | 0.140 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 10 | 0.140 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2011 | 6 | 0.140 |
Why?
|
| Social Support | 2 | 2018 | 195 | 0.140 |
Why?
|
| Patient Navigation | 1 | 2018 | 20 | 0.140 |
Why?
|
| Advance Care Planning | 1 | 2018 | 22 | 0.140 |
Why?
|
| Patient Admission | 3 | 2015 | 58 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 382 | 0.130 |
Why?
|
| Ageism | 1 | 2016 | 2 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2016 | 4 | 0.120 |
Why?
|
| Hispanic Americans | 1 | 2018 | 350 | 0.120 |
Why?
|
| Energy Metabolism | 3 | 2013 | 47 | 0.120 |
Why?
|
| Independent Living | 1 | 2016 | 24 | 0.120 |
Why?
|
| Fasting | 1 | 2016 | 45 | 0.120 |
Why?
|
| Housing | 1 | 2016 | 38 | 0.120 |
Why?
|
| Focus Groups | 1 | 2016 | 140 | 0.120 |
Why?
|
| Health Personnel | 1 | 2017 | 132 | 0.120 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 6 | 0.110 |
Why?
|
| Body Weight | 3 | 2016 | 197 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2016 | 288 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 84 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 244 | 0.110 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2013 | 10 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2014 | 71 | 0.100 |
Why?
|
| Glucose | 2 | 2011 | 29 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 117 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 374 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2013 | 30 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2012 | 4 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 4 | 0.090 |
Why?
|
| Resistance Training | 1 | 2012 | 5 | 0.090 |
Why?
|
| Thigh | 2 | 2010 | 10 | 0.090 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Cognition | 1 | 2013 | 90 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2012 | 5 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 14 | 0.090 |
Why?
|
| Thinness | 1 | 2012 | 31 | 0.090 |
Why?
|
| HIV-1 | 1 | 2012 | 72 | 0.090 |
Why?
|
| Dietary Fats | 1 | 2012 | 88 | 0.090 |
Why?
|
| Absorptiometry, Photon | 4 | 2014 | 54 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 2 | 2008 | 20 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2011 | 1 | 0.090 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 3 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 42 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 410 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 17 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2463 | 0.080 |
Why?
|
| Weight Gain | 1 | 2011 | 167 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2010 | 57 | 0.080 |
Why?
|
| Biomarkers | 4 | 2012 | 284 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 47 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2008 | 6 | 0.070 |
Why?
|
| Motor Activity | 1 | 2008 | 196 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 256 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 33 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2006 | 58 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2005 | 1 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 4 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2005 | 11 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 19 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 10 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 708 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 22 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 36 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2013 | 33 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 5 | 0.060 |
Why?
|
| Basal Metabolism | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2005 | 63 | 0.050 |
Why?
|
| Radioisotope Dilution Technique | 1 | 2004 | 1 | 0.050 |
Why?
|
| Deuterium | 1 | 2004 | 3 | 0.050 |
Why?
|
| Body Water | 1 | 2004 | 3 | 0.050 |
Why?
|
| Serum | 1 | 2004 | 4 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 291 | 0.050 |
Why?
|
| Urine | 1 | 2004 | 5 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 210 | 0.050 |
Why?
|
| Glucose Clamp Technique | 3 | 2013 | 17 | 0.050 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2004 | 11 | 0.050 |
Why?
|
| Hypoventilation | 1 | 2004 | 1 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 8 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 1204 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 41 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 24 | 0.050 |
Why?
|
| Length of Stay | 1 | 2004 | 169 | 0.050 |
Why?
|
| Terminal Care | 1 | 2003 | 48 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2003 | 58 | 0.050 |
Why?
|
| Lipids | 2 | 2013 | 66 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 6 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2012 | 6 | 0.050 |
Why?
|
| Peptides | 2 | 2012 | 14 | 0.050 |
Why?
|
| Weight Reduction Programs | 2 | 2014 | 51 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2004 | 122 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 1098 | 0.040 |
Why?
|
| Energy Intake | 2 | 2016 | 98 | 0.040 |
Why?
|
| Triglycerides | 2 | 2012 | 78 | 0.040 |
Why?
|
| Linear Models | 3 | 2008 | 187 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2003 | 247 | 0.040 |
Why?
|
| Calorimetry | 2 | 2012 | 2 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 203 | 0.040 |
Why?
|
| Fatty Acids | 2 | 2012 | 9 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 352 | 0.040 |
Why?
|
| Diet | 3 | 2009 | 349 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 520 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2011 | 925 | 0.040 |
Why?
|
| Placebos | 2 | 2011 | 19 | 0.040 |
Why?
|
| Hip | 2 | 2011 | 8 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 20 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 2013 | 108 | 0.040 |
Why?
|
| Kinetics | 2 | 2012 | 12 | 0.030 |
Why?
|
| Heart Failure | 1 | 2003 | 403 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2008 | 138 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 1233 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 317 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1997 | 9 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 23 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2016 | 22 | 0.030 |
Why?
|
| Physical Fitness | 2 | 2008 | 65 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1997 | 242 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 10 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 1058 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 325 | 0.030 |
Why?
|
| Femur Neck | 1 | 2014 | 6 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 29 | 0.020 |
Why?
|
| Mathematical Concepts | 1 | 2013 | 3 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 3 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 78 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 8 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 2 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 45 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 36 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 5 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 5 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 48 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2012 | 4 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 25 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 20 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 75 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2011 | 2 | 0.020 |
Why?
|
| Oxytocics | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 64 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 19 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 33 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 3108 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 113 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 995 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 8 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2009 | 14 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 120 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 278 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 814 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 12 | 0.020 |
Why?
|
| Testosterone | 1 | 2008 | 19 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 20 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 175 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 560 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 261 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Microdialysis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 47 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 989 | 0.020 |
Why?
|
| Femur | 1 | 2006 | 10 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 28 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2006 | 58 | 0.010 |
Why?
|
| Buttocks | 1 | 2005 | 1 | 0.010 |
Why?
|
| Vitamin D | 1 | 2006 | 75 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 19 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Premenopause | 1 | 2005 | 20 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 346 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 2456 | 0.010 |
Why?
|
| Rest | 1 | 2004 | 2 | 0.010 |
Why?
|
| C-Peptide | 1 | 2004 | 6 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 31 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 2 | 0.010 |
Why?
|
| Bicarbonates | 1 | 2004 | 3 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 18 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 18 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 207 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2003 | 7 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 191 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2003 | 7 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 114 | 0.010 |
Why?
|
| Critical Care | 1 | 2004 | 62 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 20 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 129 | 0.010 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2004 | 199 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 107 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 516 | 0.010 |
Why?
|
| Physicians | 1 | 2003 | 114 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 657 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 670 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 2396 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 677 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 3464 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1997 | 828 | 0.010 |
Why?
|